Lily Wong

Partner/Managing Director
PricewaterhouseCoopers Financial Advisory Services Co., Ltd.
​
​​

Lily Wong is a Partner in the Deals practice of PwC Taiwan and specialises in M&A advisory services, including strategic advice, due diligence and valuation analysis. Lily has a wealth of experience of conducting buy-side advisory projects for strategic and financial buyers, as well as carve-out and sell-side support, in addition to market assessments and commercial due diligence for international companies and investors looking to enter Taiwan. Lily works with clients across a range of industries, including the financial services, healthcare, pharmaceutical and life sciences, retail and consumer sectors, etc.
 
Selected advisory experience in the health industries:
Deals advisory services for local pharma and medical device companies seeking strategic and financial investors;
Sell-side lead advisor for a listed pharmaceutical company seeking to divest its China-based assets;
Valuation and financial due diligence services for several domestic biopharmaceutical companies;
Development of a comprehensive market entry strategy for leading Japanese pharmaceutical company; and
Various market assessment projects for leading multinational pharmaceutical companies operating in Taiwan. 
Lily holds Taiwan and US Certified Professional Accountant (CPA) licenses, and is also a Certified Treasury Professional (CTP) and Fellow of Life Management Institute (FLMI). She has a BA in Business Administration from the National Taiwan University, and a Masters of Accounting Science degree from the University of Illinois at Urbana-Champaign in the US.

Speech title & Synopsis

M&A trends in the health industries

M&A activity in the health industries has fluctuated in recent years at the global, regional and local levels. The presentation will examine how M&A is changing the sector’s landscape and creating transformational value for businesses and organizations across healthcare, biotechnology, pharmaceuticals and medical devices.
 
Health industries M&A is set to rebound in 2023, with investors attracted by innovation and growth prospects:
Portfolio optimization and capital allocation strategies will lead to more divestitures of non-core assets and acquisitions as companies reinvest in line with strategic priorities
Growth ambitions and gaps in pharmaceutical drug pipelines will drive deals activity
Efforts to accelerate digital transformation, especially in R&D such as AI in drug discovery 
The Taiwan market has been relatively quiet so far, but deal activity is expected to heat up on government support for the biomedical industry as local players look to grow and expand domestically and overseas.